Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1355428,tmax,"Without SASP, the tmax of TA was 2.8 h, Cmax was 112 ng.",Interaction of talinolol and sulfasalazine in the human gastrointestinal tract. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355428/),h,2.8,5106,DB00795,Sulfasalazine
,1355428,Cmax,"Without SASP, the tmax of TA was 2.8 h, Cmax was 112 ng.",Interaction of talinolol and sulfasalazine in the human gastrointestinal tract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355428/),ng,112,5107,DB00795,Sulfasalazine
,1355428,half life,ml-1 and the half life was 12 h; the AUCo-t was 958 ng.,Interaction of talinolol and sulfasalazine in the human gastrointestinal tract. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355428/),h,12,5108,DB00795,Sulfasalazine
,1355428,AUCo-t,ml-1 and the half life was 12 h; the AUCo-t was 958 ng.,Interaction of talinolol and sulfasalazine in the human gastrointestinal tract. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355428/),ng,958,5109,DB00795,Sulfasalazine
,1355428,Cmax,"In the case of concomitant administration of SASP, TA was found only in serum from 3 individuals, with a Cmax of 23 ng.",Interaction of talinolol and sulfasalazine in the human gastrointestinal tract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355428/),ng,23,5110,DB00795,Sulfasalazine
,1355428,AUCo-t,ml-1 and a mean AUCo-t of 84 ng.,Interaction of talinolol and sulfasalazine in the human gastrointestinal tract. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355428/),ng,84,5111,DB00795,Sulfasalazine
,23179005,blood flow rate,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],160-300,18219,DB00795,Sulfasalazine
,23179005,blood flow rate,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],0 and 4.3,18220,DB00795,Sulfasalazine
,23179005,clearances,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],1.1 and 3.4,18221,DB00795,Sulfasalazine
,23179005,Total amount of teriflunomide removed,Total amount of teriflunomide removed was 5.8-8.8 μg per dialysis session.,Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),μg,5.8-8.8,18222,DB00795,Sulfasalazine
,9169983,time when,"After the oral administration of SASP at the does of 25.0 mg/kg, the mean time when the plasma 5-ASA concentration reaches to its maximum (Tmax) was 9.0 hr.",Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169983/),h,9.0,38801,DB00795,Sulfasalazine
,9169983,Tmaxs,"In the case of 5-ASA administered in PCC, at the doses of 12.5 and 25.0 mg/kg, Tmaxs were 5.3 and 5.3 hr, respectively.",Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169983/),h,5.3,38802,DB00795,Sulfasalazine
,2908013,plasma levels,SP plasma levels were 17.7 +/- 9.0 ug/ml (range 6.8-36.3 ug/ml) at 6 hours after doses.,[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),[ug] / [ml],17.7,46626,DB00795,Sulfasalazine
,2908013,plasma levels,"SASP plasma levels were 15.5 +/- 15.4 ug/ml (range 2.1-53.4 ug/ml) at 6 hours after doses, and 14.0 +/- 20.4 ug/ml (range 3.9-70.7 ug/ml) at 12 hours after doses.",[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),[ug] / [ml],15.5,46627,DB00795,Sulfasalazine
,2908013,plasma levels,"SASP plasma levels were 15.5 +/- 15.4 ug/ml (range 2.1-53.4 ug/ml) at 6 hours after doses, and 14.0 +/- 20.4 ug/ml (range 3.9-70.7 ug/ml) at 12 hours after doses.",[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),[ug] / [ml],14.0,46628,DB00795,Sulfasalazine
,2908013,24 hours,The 24 hours fecal excretion was 17.4 to 236 mg.,[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),mg,17.4 to 236,46629,DB00795,Sulfasalazine
,2908013,fecal excretion,The 24 hours fecal excretion was 17.4 to 236 mg.,[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),mg,17.4 to 236,46630,DB00795,Sulfasalazine
,6123257,Peak serum 5-ASA concentration,Peak serum 5-ASA concentration (55 micrograms/ml) was reached in 1 h.,"Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6123257/),[μg] / [ml],55,55904,DB00795,Sulfasalazine
,6123257,peak serum concentration,"When sulfapyridine (20 mg) was administered in addition to 5-ASA, 70% of the sulfapyridine was absorbed in the small intestine, peak serum concentration (50 micrograms/ml) was reached in 1 h, and 30% of the administered dose was excreted in the urine in 24 h.","Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6123257/),[μg] / [ml],50,55905,DB00795,Sulfasalazine
,21251889,total run time,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,9.0,59775,DB00795,Sulfasalazine
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,4.8,59776,DB00795,Sulfasalazine
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.5,59777,DB00795,Sulfasalazine
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.0,59778,DB00795,Sulfasalazine
,8104772,local bioavailability,"The local bioavailability in the distal gut lumen, reflected by the 5-aminosalicylic acid concentration in the fecal water, showed comparable values after Pentasa (4.44 mmol/liter) and Salazopyrin (6.25 mmol/liter).",Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),[mM] / [l],4.44,72014,DB00795,Sulfasalazine
,8104772,local bioavailability,"The local bioavailability in the distal gut lumen, reflected by the 5-aminosalicylic acid concentration in the fecal water, showed comparable values after Pentasa (4.44 mmol/liter) and Salazopyrin (6.25 mmol/liter).",Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),[mM] / [l],6.25,72015,DB00795,Sulfasalazine
,8104772,urinary excretion,The urinary excretion of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid was higher after Pentasa than after Salazopyrin (32% vs 25%).,Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),%,32,72016,DB00795,Sulfasalazine
,8104772,urinary excretion,The urinary excretion of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid was higher after Pentasa than after Salazopyrin (32% vs 25%).,Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),%,25,72017,DB00795,Sulfasalazine
,7905389,mean residence time,"Upon intravenous administration, SASP rapidly disappeared from blood with a mean residence time of 0.45-0.78 hr.",Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905389/),h,0.45-0.78,76128,DB00795,Sulfasalazine
,7905389,absolute oral bioavailability,"In both sexes, the absolute oral bioavailability of SASP ranged between 16.6-18.2% at a dose of 67.5 mg/kg, and between 2.6-8.7% at doses of 675-2700 mg/kg.",Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905389/),%,16.6-18.2,76129,DB00795,Sulfasalazine
,7905389,absolute oral bioavailability,"In both sexes, the absolute oral bioavailability of SASP ranged between 16.6-18.2% at a dose of 67.5 mg/kg, and between 2.6-8.7% at doses of 675-2700 mg/kg.",Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905389/),%,2.6-8.7,76130,DB00795,Sulfasalazine
,33671835,brain to plasma ratio,The concentration of SAS in brain was much lower than that in plasma and only 1.26% of SAS was detected in mouse brain when compared to the SAS concentration in plasma (brain to plasma ratio (%): 1.26).,Quantification and Metabolite Identification of Sulfasalazine in Mouse Brain and Plasma Using Quadrupole-Time-of-Flight Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33671835/),,1.26,79273,DB00795,Sulfasalazine
,2877884,24-hour recoveries,"The 24-hour recoveries of the drugs were 90.5% and 84.7%, respectively.",5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,90.5,80941,DB00795,Sulfasalazine
,2877884,24-hour recoveries,"The 24-hour recoveries of the drugs were 90.5% and 84.7%, respectively.",5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,84.7,80942,DB00795,Sulfasalazine
,2877884,release,The median release of 5-ASA from SASP was 50% and from Pentasa 75%.,5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,50,80943,DB00795,Sulfasalazine
,2877884,release,The median release of 5-ASA from SASP was 50% and from Pentasa 75%.,5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,75,80944,DB00795,Sulfasalazine
,19560446,AUC(0)(-)(72),"The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172.57+/-49.42, 103.38+/-39.85, 71.37+/-17.52mg h/l, and 9.65+/-2.34, 6.10+/-1.79, 4.55+/-1.38mg/l, respectively.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[h·mg] / [l],172.57,81332,DB00795,Sulfasalazine
,19560446,AUC(0)(-)(72),"The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172.57+/-49.42, 103.38+/-39.85, 71.37+/-17.52mg h/l, and 9.65+/-2.34, 6.10+/-1.79, 4.55+/-1.38mg/l, respectively.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[h·mg] / [l],103.38,81333,DB00795,Sulfasalazine
,19560446,AUC(0)(-)(72),"The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172.57+/-49.42, 103.38+/-39.85, 71.37+/-17.52mg h/l, and 9.65+/-2.34, 6.10+/-1.79, 4.55+/-1.38mg/l, respectively.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[h·mg] / [l],71.37,81334,DB00795,Sulfasalazine
,19560446,Cmax,"The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172.57+/-49.42, 103.38+/-39.85, 71.37+/-17.52mg h/l, and 9.65+/-2.34, 6.10+/-1.79, 4.55+/-1.38mg/l, respectively.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[h·mg] / [l],103.38,81335,DB00795,Sulfasalazine
,19560446,Cmax,"The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172.57+/-49.42, 103.38+/-39.85, 71.37+/-17.52mg h/l, and 9.65+/-2.34, 6.10+/-1.79, 4.55+/-1.38mg/l, respectively.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[h·mg] / [l],71.37,81336,DB00795,Sulfasalazine
,19560446,Cmax,"The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172.57+/-49.42, 103.38+/-39.85, 71.37+/-17.52mg h/l, and 9.65+/-2.34, 6.10+/-1.79, 4.55+/-1.38mg/l, respectively.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[mg] / [l],9.65,81337,DB00795,Sulfasalazine
,19560446,Cmax,"The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172.57+/-49.42, 103.38+/-39.85, 71.37+/-17.52mg h/l, and 9.65+/-2.34, 6.10+/-1.79, 4.55+/-1.38mg/l, respectively.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[mg] / [l],6.10,81338,DB00795,Sulfasalazine
,19560446,Cmax,"The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172.57+/-49.42, 103.38+/-39.85, 71.37+/-17.52mg h/l, and 9.65+/-2.34, 6.10+/-1.79, 4.55+/-1.38mg/l, respectively.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[mg] / [l],4.55,81339,DB00795,Sulfasalazine
,19560446,Cmax,"The Cmax of AcSP in w/w, w/m and m/m subjects was 12.67+/-3.32, 9.07+/-2.29 and 4.22+/-0.93mg/l, respectively, with significant differences among groups.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[mg] / [l],12.67,81340,DB00795,Sulfasalazine
,19560446,Cmax,"The Cmax of AcSP in w/w, w/m and m/m subjects was 12.67+/-3.32, 9.07+/-2.29 and 4.22+/-0.93mg/l, respectively, with significant differences among groups.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[mg] / [l],9.07,81341,DB00795,Sulfasalazine
,19560446,Cmax,"The Cmax of AcSP in w/w, w/m and m/m subjects was 12.67+/-3.32, 9.07+/-2.29 and 4.22+/-0.93mg/l, respectively, with significant differences among groups.",Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560446/),[mg] / [l],4.22,81342,DB00795,Sulfasalazine
,19569219,plasma AUC((0-infinity)),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[h·μg] / [ml],32.1,89963,DB00795,Sulfasalazine
,19569219,plasma AUC((0-infinity)),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[h·μg] / [ml],16.8,89964,DB00795,Sulfasalazine
,19569219,plasma AUC((0-infinity)),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[h·μg] / [ml],62.7,89965,DB00795,Sulfasalazine
,19569219,C(max),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[μg] / [ml],4.01,89966,DB00795,Sulfasalazine
,19569219,C(max),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[μg] / [ml],1.70,89967,DB00795,Sulfasalazine
,19569219,C(max),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[μg] / [ml],6.86,89968,DB00795,Sulfasalazine
,22300367,K(i),KEY RESULTS Curcumin was a potent hBCRP inhibitor in vitro (K(i) 0.70 ± 0.41 µM).,Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300367/),μM,0.70,91237,DB00795,Sulfasalazine
,22300367,K(m),Sulphasalazine was a substrate for OATP2B1 (K(m) 1.7 ± 0.3 µM).,Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300367/),μM,1.7,91238,DB00795,Sulfasalazine
,17541571,K(,The K(M6G_abs)/K(M6G_M6G) ratio was found to be 10.,Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541571/),,10,92595,DB00795,Sulfasalazine
,17541571,K,The K(M6G_abs)/K(M6G_M6G) ratio was found to be 10.,Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541571/),,10,92596,DB00795,Sulfasalazine
,17541571,K,The K(M6G_abs)/K(M6G_M6G) ratio of 10 indicates that the second absorption peak of M6G consists of approximately 10 times more absorbed M6G than reglucuronidated M6G.,Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541571/),,10,92597,DB00795,Sulfasalazine
,7659853,OCTT,"However, the median OCTT assessed by the BH2T (135 minutes, range 120 to 195 minutes) was not significantly different from that measured by the SLZ (180 minutes, range 150 to 210 minutes) and was highly correlated with it (r = 0.94, P = 0.016).",A comparison of orocaecal transit times assessed by the breath hydrogen test and the sulphasalazine/sulphapyridine method in healthy beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7659853/),min,135,99233,DB00795,Sulfasalazine
,7659853,OCTT,"However, the median OCTT assessed by the BH2T (135 minutes, range 120 to 195 minutes) was not significantly different from that measured by the SLZ (180 minutes, range 150 to 210 minutes) and was highly correlated with it (r = 0.94, P = 0.016).",A comparison of orocaecal transit times assessed by the breath hydrogen test and the sulphasalazine/sulphapyridine method in healthy beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7659853/),min,180,99234,DB00795,Sulfasalazine
,12534638,clearance,"For a typical subject in the population, a clearance of 0.377 l h-1 (95% confidence interval (CI) 0.0304-0.449) in males and 0.347 l h-1 (95% CI 0.274-0.419) in females was obtained.",Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534638/),[l] / [h],0.377,115904,DB00795,Sulfasalazine
,12534638,clearance,"For a typical subject in the population, a clearance of 0.377 l h-1 (95% confidence interval (CI) 0.0304-0.449) in males and 0.347 l h-1 (95% CI 0.274-0.419) in females was obtained.",Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534638/),[l] / [h],0.347,115905,DB00795,Sulfasalazine
,12534638,volume of distribution,The volume of distribution was estimated to be 14.9 l.,Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534638/),l,14.9,115906,DB00795,Sulfasalazine
,2565380,steady state plasma level,Range of variable steady state plasma level of 5-ASA was 0.1-5 mg/L and of its acetyl-metabolite (Ac-5-ASA) was 1-8 mg/L.,Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565380/),[mg] / [l],0.1-5,134318,DB00795,Sulfasalazine
,2565380,steady state plasma level,Range of variable steady state plasma level of 5-ASA was 0.1-5 mg/L and of its acetyl-metabolite (Ac-5-ASA) was 1-8 mg/L.,Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565380/),[mg] / [l],1-8,134319,DB00795,Sulfasalazine
,10123,area under the serum digoxin curve,"When digoxin was given with SSA, the average area under the serum digoxin curve fell from the control value of 8.79 ng-hr-ml(-1) to 6.66 ng-hr-ml(-1) (p less than 0.05), fell and total urinary excretion decreased from 278 mcg/10 days to 228 mcg/10 days (p less than 0.025).",Effect of sulfasalazine on digoxin bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10123/),1/[ng-hr-ml],8.79,135287,DB00795,Sulfasalazine
,10123,area under the serum digoxin curve,"When digoxin was given with SSA, the average area under the serum digoxin curve fell from the control value of 8.79 ng-hr-ml(-1) to 6.66 ng-hr-ml(-1) (p less than 0.05), fell and total urinary excretion decreased from 278 mcg/10 days to 228 mcg/10 days (p less than 0.025).",Effect of sulfasalazine on digoxin bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10123/),1/[ng-hr-ml],6.66,135288,DB00795,Sulfasalazine
,10123,total urinary excretion,"When digoxin was given with SSA, the average area under the serum digoxin curve fell from the control value of 8.79 ng-hr-ml(-1) to 6.66 ng-hr-ml(-1) (p less than 0.05), fell and total urinary excretion decreased from 278 mcg/10 days to 228 mcg/10 days (p less than 0.025).",Effect of sulfasalazine on digoxin bioavailability. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10123/),[mcg] / [10·d],278,135289,DB00795,Sulfasalazine
,10123,total urinary excretion,"When digoxin was given with SSA, the average area under the serum digoxin curve fell from the control value of 8.79 ng-hr-ml(-1) to 6.66 ng-hr-ml(-1) (p less than 0.05), fell and total urinary excretion decreased from 278 mcg/10 days to 228 mcg/10 days (p less than 0.025).",Effect of sulfasalazine on digoxin bioavailability. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10123/),[mcg] / [10·d],228,135290,DB00795,Sulfasalazine
,2864155,elimination half-life,Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process.,"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,5 to 10,139123,DB00795,Sulfasalazine
,2864155,elimination half-life,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,14,139124,DB00795,Sulfasalazine
,2864155,elimination half-life,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,6,139125,DB00795,Sulfasalazine
,2864155,apparent oral clearance,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[ml] / [min],40,139126,DB00795,Sulfasalazine
,2864155,apparent oral clearance,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[ml] / [min],150,139127,DB00795,Sulfasalazine
,2864155,elimination half-life,"While the elimination half-life of 5-ASA is short (0.5 to 1.5 h), its major acetylated metabolite (which may be active) exhibits a half-life of 5 to 10 hours.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,0.5 to 1.5,139128,DB00795,Sulfasalazine
,2864155,half-life,"While the elimination half-life of 5-ASA is short (0.5 to 1.5 h), its major acetylated metabolite (which may be active) exhibits a half-life of 5 to 10 hours.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,5 to 10,139129,DB00795,Sulfasalazine
less,2864155,steady-state plasma concentrations,"During therapy with sulphasalazine or 5-ASA, steady-state plasma concentrations of 5-ASA are relatively low (less than or equal to 2 micrograms/ml); thus its mode of action appears to be topically rather than systemically.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[μg] / [ml],2,139130,DB00795,Sulfasalazine
,33201,systemic availability,"The low relative extent of systemic availability of sulfapyridine from the enteric-coated tablets (65.5 +/- 6.3 per cent, mean +/- S.E.) compared to uncoated tablets may be due to absorption rate-dependent presystemic metabolism, since the relative extent of sulfapyridine absorption was 92.7 +/- 6.2 per cent compared to uncoated tablets.",Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33201/),%,65.5,140766,DB00795,Sulfasalazine
,33201,relative extent,"The low relative extent of systemic availability of sulfapyridine from the enteric-coated tablets (65.5 +/- 6.3 per cent, mean +/- S.E.) compared to uncoated tablets may be due to absorption rate-dependent presystemic metabolism, since the relative extent of sulfapyridine absorption was 92.7 +/- 6.2 per cent compared to uncoated tablets.",Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33201/),%,92.7,140767,DB00795,Sulfasalazine
,33201,absorption,"The low relative extent of systemic availability of sulfapyridine from the enteric-coated tablets (65.5 +/- 6.3 per cent, mean +/- S.E.) compared to uncoated tablets may be due to absorption rate-dependent presystemic metabolism, since the relative extent of sulfapyridine absorption was 92.7 +/- 6.2 per cent compared to uncoated tablets.",Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33201/),%,92.7,140768,DB00795,Sulfasalazine
,8864317,AUC,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[ng] / [ml],673,142186,DB00795,Sulfasalazine
,8864317,AUC,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[ng] / [ml],628,142187,DB00795,Sulfasalazine
,8864317,MRT,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),h,5.2,142188,DB00795,Sulfasalazine
,8864317,MRT,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),h,5.2,142189,DB00795,Sulfasalazine
,8864317,"t1/2,z","3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),h,4.3,142190,DB00795,Sulfasalazine
,8864317,"t1/2,z","3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),h,4.2,142191,DB00795,Sulfasalazine
,8864317,V/F,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),1,59.3,142192,DB00795,Sulfasalazine
,8864317,V/F,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),1,65.5,142193,DB00795,Sulfasalazine
,8864317,CL/F,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[1] / [h],12.3,142194,DB00795,Sulfasalazine
,8864317,CL/F,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[1] / [h],13.5,142195,DB00795,Sulfasalazine
,8864317,CLR/F,CLR/F: 6.2 +/- 1.3 vs 6.3 +/- 2.1 (95% CI -1.3 to 1.1) l h-1.,Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[l] / [h],6.2,142196,DB00795,Sulfasalazine
,8864317,CLR/F,CLR/F: 6.2 +/- 1.3 vs 6.3 +/- 2.1 (95% CI -1.3 to 1.1) l h-1.,Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[l] / [h],6.3,142197,DB00795,Sulfasalazine
,10197419,biliary concentrations,"Extremely high biliary concentrations of unchanged susalimod (20,000-43,000 microM) were measured.","Efficient biliary excretion of susalimod, probably via the bromosulphthalein carrier, studied in a chronic bile fistula model in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10197419/),μM,"20,000-43,000",143216,DB00795,Sulfasalazine
,10197419,maximal bile/plasma concentration ratio,The maximal bile/plasma concentration ratio was 4300.,"Efficient biliary excretion of susalimod, probably via the bromosulphthalein carrier, studied in a chronic bile fistula model in dogs. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10197419/),,4300,143217,DB00795,Sulfasalazine
,16686369,bioavailability,"When administered orally, sulfasalazine is poorly absorbed with an estimated bioavailability of 3-12%.",Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16686369/),%,3-12,144972,DB00795,Sulfasalazine
,31371478,IC50,"Dotinurad, benzbromarone, lesinurad, and probenecid inhibited urate transporter 1 (URAT1) with IC50 values of 0.0372, 0.190, 30.0, and 165 μM, respectively.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,0.0372,151352,DB00795,Sulfasalazine
,31371478,IC50,"Dotinurad, benzbromarone, lesinurad, and probenecid inhibited urate transporter 1 (URAT1) with IC50 values of 0.0372, 0.190, 30.0, and 165 μM, respectively.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,0.190,151353,DB00795,Sulfasalazine
,31371478,IC50,"Dotinurad, benzbromarone, lesinurad, and probenecid inhibited urate transporter 1 (URAT1) with IC50 values of 0.0372, 0.190, 30.0, and 165 μM, respectively.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,30.0,151354,DB00795,Sulfasalazine
,31371478,IC50,"Dotinurad, benzbromarone, lesinurad, and probenecid inhibited urate transporter 1 (URAT1) with IC50 values of 0.0372, 0.190, 30.0, and 165 μM, respectively.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,165,151355,DB00795,Sulfasalazine
,31371478,IC50,"Dotinurad weakly inhibited ATP-binding cassette subfamily G member 2 (ABCG2), organic anion transporter 1 (OAT1), and OAT3, with IC50 values of 4.16, 4.08, and 1.32 μM, respectively, indicating higher selectivity for URAT1.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,4.16,151356,DB00795,Sulfasalazine
,31371478,IC50,"Dotinurad weakly inhibited ATP-binding cassette subfamily G member 2 (ABCG2), organic anion transporter 1 (OAT1), and OAT3, with IC50 values of 4.16, 4.08, and 1.32 μM, respectively, indicating higher selectivity for URAT1.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,4.08,151357,DB00795,Sulfasalazine
,31371478,IC50,"Dotinurad weakly inhibited ATP-binding cassette subfamily G member 2 (ABCG2), organic anion transporter 1 (OAT1), and OAT3, with IC50 values of 4.16, 4.08, and 1.32 μM, respectively, indicating higher selectivity for URAT1.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,1.32,151358,DB00795,Sulfasalazine
,10490905,potency (IC(50)),"Because the results supported the assumption that the maximum inhibitory effect was equal to full inhibition of the synthesis, the in vivo potency (IC(50)) of susalimod could be estimated to 293 microM.",Pharmacokinetic-pharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-alpha levels in the mouse. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490905/),μM,293,167676,DB00795,Sulfasalazine
,10490905,potency,The integrated pharmacokinetic-pharmacodynamic model estimated the in vivo potency of susalimod in the mouse to be 293 microM.,Pharmacokinetic-pharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-alpha levels in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490905/),μM,293,167677,DB00795,Sulfasalazine
less,10976656,maximal plasma concentrations,"Most studies report maximal plasma concentrations of less than 1 mg/L after oral administration of slow release mesalazine, much lower than those observed after uncoated mesalazine but generally higher than after azo-bound drugs such as sulfasalazine.",Clinical pharmacokinetics of slow release mesalazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976656/),[mg] / [l],1,175041,DB00795,Sulfasalazine
,10976656,steady-state concentrations,Mean steady-state concentrations of 25.7+/-2.2 microg/kg wet weight are found in ileocolonic biopsy specimens from patients with irritable bowel syndrome treated for 1 week with slow release mesalazine 1.5 g/day.,Clinical pharmacokinetics of slow release mesalazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976656/),[μg] / [kg·weight·wet],25.7,175042,DB00795,Sulfasalazine
,2897213,volume of distribution,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),1/[lkg],0.667,192515,DB00795,Sulfasalazine
,2897213,half-life,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),h,9.7,192516,DB00795,Sulfasalazine
,2897213,oral clearance,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),[min] / [kg·ml],0.852,192517,DB00795,Sulfasalazine
greater,7904547,elimination half-lives,Both drugs have reported elimination half-lives of greater than 1 month.,Clinical pharmacokinetics of slow-acting antirheumatic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904547/),month,1,193639,DB00795,Sulfasalazine
,11853180,maximum concentration (Cmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,2.5,194755,DB00795,Sulfasalazine
,11853180,maximum concentration (Cmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,0.5,194756,DB00795,Sulfasalazine
,11853180,time to Cmax (Tmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,5,194757,DB00795,Sulfasalazine
,11853180,time to Cmax (Tmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,12,194758,DB00795,Sulfasalazine
,11853180,Cmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,5.8,194759,DB00795,Sulfasalazine
,11853180,Tmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,13.3,194760,DB00795,Sulfasalazine
,11853180,Tmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,1,194761,DB00795,Sulfasalazine
,11853180,Tmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,7,194762,DB00795,Sulfasalazine
,11853180,area under the serum concentration-time curve (AUC),"The area under the serum concentration-time curve (AUC) of SASP was 27.4+/-4.8 microM x h, a finding similar to that of 5-ASA after the administration of the 5-ASA enema (29.4+/-11.1 microM x h).",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h·μM,27.4,194763,DB00795,Sulfasalazine
,11853180,area under the serum concentration-time curve (AUC),"The area under the serum concentration-time curve (AUC) of SASP was 27.4+/-4.8 microM x h, a finding similar to that of 5-ASA after the administration of the 5-ASA enema (29.4+/-11.1 microM x h).",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h·μM,29.4,194764,DB00795,Sulfasalazine
,11853180,percentage of urinary recovery,The percentage of urinary recovery of SASP 24 h after administration of the SASP suppository was approximately 0.2%.,Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),%,0.2,194765,DB00795,Sulfasalazine
more,11853180,urinary recovery,"On the other hand, approximately 0.3% of 5-ASA was recovered in the urine in unchanged form after the administration of the 5-ASA enema, whereas the urinary recovery of Ac-5-ASA was more than 10%.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),%,10,194766,DB00795,Sulfasalazine
,747,lambdamax,The violet colored product of the Bratton-Marshall reaction has a lambdamax of 560 nm and conforms to Beer's law over the concentration range of 0-70 umg/ml.,Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747/),nm,560,198450,DB00795,Sulfasalazine
,747,recoveries,"Average recoveries (+/- S.D., N = 6) OF 5-ASA added to rat and human urine and rat fecal homogenates were 91.6 +/- 4.9%, 102 +/- 6.0%, and 71.0 +/- 4.8%, respectively.",Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747/),%,91.6,198451,DB00795,Sulfasalazine
,747,recoveries,"Average recoveries (+/- S.D., N = 6) OF 5-ASA added to rat and human urine and rat fecal homogenates were 91.6 +/- 4.9%, 102 +/- 6.0%, and 71.0 +/- 4.8%, respectively.",Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747/),%,102,198452,DB00795,Sulfasalazine
,747,recoveries,"Average recoveries (+/- S.D., N = 6) OF 5-ASA added to rat and human urine and rat fecal homogenates were 91.6 +/- 4.9%, 102 +/- 6.0%, and 71.0 +/- 4.8%, respectively.",Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747/),%,71.0,198453,DB00795,Sulfasalazine
,2518847,urinary recovery,Median urinary recovery values were 21.7% for Salazopyrin and 35.5% for Mesasal (fasting) (P less than 0.01).,Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,21.7,203986,DB00795,Sulfasalazine
,2518847,urinary recovery,Median urinary recovery values were 21.7% for Salazopyrin and 35.5% for Mesasal (fasting) (P less than 0.01).,Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,35.5,203987,DB00795,Sulfasalazine
,2518847,total faecal recovery,"The total faecal recovery values were 38.3 and 26.5%, respectively (NS).",Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,38.3,203988,DB00795,Sulfasalazine
,2518847,total faecal recovery,"The total faecal recovery values were 38.3 and 26.5%, respectively (NS).",Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,26.5,203989,DB00795,Sulfasalazine
,2518847,urinary recovery,Suppository administration of 5-ASA resulted in a low median urinary recovery of 10.8%.,Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,10.8,203990,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,11-33,228618,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,22,228619,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,14-31,228620,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,16-27,228621,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,12-35,228622,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,20,228623,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,10-35,228624,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,18-40,228625,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,15-53,228626,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,23-34,228627,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,27-56,228628,DB00795,Sulfasalazine
,12492730,urinary excretion,": Pharmacokinetic data (Tmax, Cmax, AUC, urinary excretion, faecal excretion) of 5ASA, its major metabolite N-Acetyl-5ASA, total 5ASA, and the parent pro-drug compounds was extracted. : The summary results for urinary excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 11-33% or median 22%; olsalazine mean 14-31% or median 16-27%; balsalazide mean 12-35% or median 20%; Asacol mean 10-35% or median 18-40%; Pentasa mean 15-53% or median 23-34%; Salofalk, Mesasal and Claversal mean 27-56% or median 31-44%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,31-44,228629,DB00795,Sulfasalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,23-75,228630,DB00795,Sulfasalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,38,228631,DB00795,Sulfasalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,47-50,228632,DB00795,Sulfasalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,17-36,228633,DB00795,Sulfasalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,46,228634,DB00795,Sulfasalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,22,228635,DB00795,Sulfasalazine
,12492730,faecal excretion,"The summary results for faecal excretion of total 5ASA over 24-96 h in all subjects (either mean or median) were: sulfasalazine mean 23-75% or median 38%; olsalazine mean 47-50% or median 17-36%; balsalazide mean 46% or median 22%; Asacol mean 40-64% or median 20-56%; Pentasa mean 12-51% or median 39-59%; Salofalk, Mesasal and Claversal mean 37-44% or median 23-35%.",Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492730/),%,37-44,228636,DB00795,Sulfasalazine
,21768,apparent absorption t1/2s,SP absorption commenced 3.5 to 6 hr after sulfasalazine administration and occurred slowly (apparent absorption t1/2s ranged from 1.6 to 5 hr) irrespective of acetylator phenotype.,Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21768/),h,1.6 to 5,229767,DB00795,Sulfasalazine
,21768,saliva:plasma concentration ratio,The saliva:plasma concentration ratio for SP was 0.559 +/- 0.027 (mean of 5 subjects +/- SE) and was dependent of plasma concentration and saliva pH.,Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21768/),,0.559,229768,DB00795,Sulfasalazine
,21768,saliva:plasma concentration ratio,"The mean saliva:plasma concentration ratio for AcSP was lower (0.246 +/- 0.056), consistent with the pH-partition hypothesis, and showed considerably more intrasubject and intersubject variation than the ratio for SP.",Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21768/),,0.246,229769,DB00795,Sulfasalazine
,2871853,oral/intravenous availability ratio,The oral/intravenous availability ratio was 0.97 +/- 0.2 in the Crohn's patients and 0.90 +/- 0.1 in the colitics (mean +/- s.e. mean).,Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871853/),,0.97,231815,DB00795,Sulfasalazine
,2871853,oral/intravenous availability ratio,The oral/intravenous availability ratio was 0.97 +/- 0.2 in the Crohn's patients and 0.90 +/- 0.1 in the colitics (mean +/- s.e. mean).,Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871853/),,0.90,231816,DB00795,Sulfasalazine
,2871853,Plasma clearance,"Plasma clearance was 3.24 +/- 0.2 l h-1 and 4.1 +/- 0.5 l h-1, respectively.",Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871853/),[l] / [h],3.24,231817,DB00795,Sulfasalazine
,2871853,Plasma clearance,"Plasma clearance was 3.24 +/- 0.2 l h-1 and 4.1 +/- 0.5 l h-1, respectively.",Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871853/),[l] / [h],4.1,231818,DB00795,Sulfasalazine
,3319458,steady state plasma levels,Mean steady state plasma levels of unchanged 5-ASA are rather low (range 0.02 to 1.2 microgram/ml) whereas those of Ac-5-ASA are always higher (range 0.1 to 2.9 micrograms/ml).,Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),[μg] / [ml],0.02 to 1.2,232245,DB00795,Sulfasalazine
,3319458,steady state plasma levels,Mean steady state plasma levels of unchanged 5-ASA are rather low (range 0.02 to 1.2 microgram/ml) whereas those of Ac-5-ASA are always higher (range 0.1 to 2.9 micrograms/ml).,Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),[μg] / [ml],0.1 to 2.9,232246,DB00795,Sulfasalazine
,3319458,t1/2,"This is due to the rapid elimination of 5-ASA (t1/2 = 0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2 = 6 to 9 h, renal clearance = 200 to 300 ml/min).",Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),h,0.4 to 2.4,232247,DB00795,Sulfasalazine
,3319458,t1/2,"This is due to the rapid elimination of 5-ASA (t1/2 = 0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2 = 6 to 9 h, renal clearance = 200 to 300 ml/min).",Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),h,6 to 9,232248,DB00795,Sulfasalazine
,3319458,renal clearance,"This is due to the rapid elimination of 5-ASA (t1/2 = 0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2 = 6 to 9 h, renal clearance = 200 to 300 ml/min).",Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),[ml] / [min],200 to 300,232249,DB00795,Sulfasalazine
,9129563,peak serum concentration,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[pM] / [ml],13.9,242602,DB00795,Sulfasalazine
,9129563,peak serum concentration,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[pM] / [ml],0.68,242603,DB00795,Sulfasalazine
,9129563,area under the serum concentration-time curve,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[h·pM] / [ml],27.8,242604,DB00795,Sulfasalazine
,9129563,area under the serum concentration-time curve,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[h·pM] / [ml],1.9,242605,DB00795,Sulfasalazine
,9129563,total amount of morphine excreted in urine,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),μM,0.160,242606,DB00795,Sulfasalazine
,9129563,total amount of morphine excreted in urine,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),μM,0.015,242607,DB00795,Sulfasalazine
,32357395,IC50,"The transcellular efflux of prazosin, a stereotypical BCRP substrate, was also significantly reduced in the presence of quercetin in a bidirectional transport assay using human BCRP-overexpressing cells; further kinetic analysis revealed IC50 and Ki values of 4.22 and 3.91 μM, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),μM,4.22,244361,DB00795,Sulfasalazine
,32357395,Ki,"The transcellular efflux of prazosin, a stereotypical BCRP substrate, was also significantly reduced in the presence of quercetin in a bidirectional transport assay using human BCRP-overexpressing cells; further kinetic analysis revealed IC50 and Ki values of 4.22 and 3.91 μM, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),μM,3.91,244362,DB00795,Sulfasalazine
,32357395,AUC8h,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[min∙μg] / [ml],44.5,244363,DB00795,Sulfasalazine
,32357395,AUC8h,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[min∙μg] / [ml],25.7,244364,DB00795,Sulfasalazine
,32357395,Cmax,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[ng] / [ml],179,244365,DB00795,Sulfasalazine
,32357395,Cmax,"Moreover, pretreatment with 10 mg/kg quercetin in rats led to a 1.8-fold and 1.5-fold increase in the AUC8h (i.e., 44.5 ± 11.8 min∙μg/mL vs. 25.7 ± 9.98 min∙μg/mL, p < 0.05) and Cmax (i.e., 179 ± 23.0 ng/mL vs. 122 ± 23.2 ng/mL, p < 0.05) of orally administered sulfasalazine, respectively.",Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32357395/),[ng] / [ml],122,244366,DB00795,Sulfasalazine
,12000534,peak concentrations,"Evaluation of the plasma pharmacokinetics revealed a rapid, but low extent of absorption of OLZ (peak concentrations around 1 microg/mL at 0.5-1.5 h), and a delayed minimal absorption of 5-ASA (concentrations < 0.2 microg/mL, at 11-35 h), which is immediately metabolized to Ac-5-ASA.",Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000534/),[μg] / [ml],1,245894,DB00795,Sulfasalazine
,12000534,C(max),"As indicators of the local availability in the colon, high faecal water concentrations of 5-ASA and Ac-5-ASA (mean C(max) about 300 and 130 microg/mL, respectively), but only traces of OLZ were found in faeces excreted 18-50 h after dosing.",Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000534/),[μg] / [ml],300,245895,DB00795,Sulfasalazine
,12000534,C(max),"As indicators of the local availability in the colon, high faecal water concentrations of 5-ASA and Ac-5-ASA (mean C(max) about 300 and 130 microg/mL, respectively), but only traces of OLZ were found in faeces excreted 18-50 h after dosing.",Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000534/),[μg] / [ml],130,245896,DB00795,Sulfasalazine
,12000534,bioavailability,"The pharmacokinetic evaluation showed a very low bioavailability of 2.4% for 5-ASA, released from orally administered OLZ.",Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000534/),%,2.4,245897,DB00795,Sulfasalazine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.31,259420,DB00795,Sulfasalazine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.62,259421,DB00795,Sulfasalazine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.71,259422,DB00795,Sulfasalazine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.83,259423,DB00795,Sulfasalazine
